peaka glp-1 JCI GLP-1 Synthetic Peptide Analog |
Description
The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited
Cao TXD, Filliter C, Montastruc F, Yu OHY, Fergusson E, Rej S, et al
In the 2016 to 2025 period, the overall market size of the oral GLP-1 agonists market in the US is projected to be valued at USD 43.8 billion in 2025
Einbinder Y, Ohana M, Benchetrit S, Zehavi T, Nacasch N, Bernheim J, et al
Collectively, such findings are remarkable in that they suggest a new strategy in which the co-existing metabolic disorders of type 2 diabetes and obesity will be treatable using a single peptide such as EP45 that lowers levels of blood glucose by virtue of its GLP-1R-mediated effect, while simultaneously suppressing appetite by virtue of its NPY2R-mediated effect
And the quintuple agonist profile is incredibly elegant mechanistically
